NCT Number: NCT05785741
Phase: Phase 1|Phase 2
Trial Summary: This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors. – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): DualityBio Inc.
Acronym:
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives